Jeffrey Eisele - 23 Feb 2023 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Role
Chief Development Officer
Signature
/s/ David Watson, attorney-in-fact for Jeffrey Eisele
Issuer symbol
APLS
Transactions as of
23 Feb 2023
Transactions value $
-$113,179
Form type
4
Filing time
27 Feb 2023, 15:34:36 UTC
Previous filing
22 Feb 2023
Next filing
28 Dec 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APLS Common Stock Sale -$113,178 -1,646 -2.96% $68.76 53,883 23 Feb 2023 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Sale originated from established 10b5-1 trading plan.